Semaglutide and Pregnancy: What to Know

If you take semaglutide and you are thinking about having a baby, or you have just found out you are pregnant, the question arrives with a mix of urgency and worry. The short answer, according to the FDA label, is both clear and reassuring when it is planned for: GLP-1 medications like semaglutide are not recommended during pregnancy, and the label advises discontinuing semaglutide at least 2 months before a planned pregnancy because of its long half-life.

That does not mean something is wrong or that you should be alarmed. It means timing matters, and that with a little planning this is an orderly conversation with your care team, not an emergency. Here is why the recommendation exists, what the science says about how long the medication stays in the body, and what to do in each situation. All of it is grounded in FDA prescribing information. None of it replaces guidance from your clinician.

Why it is not recommended during pregnancy

The FDA label is direct: when a pregnancy is recognized, semaglutide should be discontinued. There are two reasons behind that instruction, and it helps to understand both without overstating them.

The first is a lack of adequate human data. The label itself notes that the available pharmacovigilance data and data from clinical trials in pregnant patients are insufficient to establish, or to rule out, a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In other words, it has not been studied enough in pregnancy to be considered safe, and in medicine the absence of proof of safety is handled with caution.

The second reason comes from the animal studies. In rats, rabbits, and monkeys, giving semaglutide during organogenesis was associated with early pregnancy losses, structural abnormalities, and alterations in growth, in some cases at exposures below the maximum recommended human dose. The label sums it up this way: based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy.

There is a third point the FDA raises that helps explain the reasoning: weight loss offers no benefit to a pregnant patient and may cause fetal harm. Pregnancy is a time when appropriate weight gain based on pre-pregnancy weight is recommended, which is the opposite of semaglutide’s main effect.

The science: long half-life and why timing matters

To understand the recommendation to stop two months ahead, it helps to look at how the molecule behaves in the body.

Semaglutide is a GLP-1 receptor agonist: it mimics a natural gut hormone that regulates appetite and fullness. But what matters here is how long it lasts. According to the prescribing information, semaglutide has an elimination half-life of approximately one week, and by design it stays in the circulation for roughly 5 to 7 weeks after the last dose.

This is semaglutide, a GLP-1 receptor agonist. Its long half-life of about one week means it stays in the body for several weeks, which is why the label advises stopping it well in advance (about 2 months) before trying to conceive.

That is the reason for the two-month window. It is not an arbitrary number: it is meant to give the medication enough time to clear before conception, rather than have it still present during the earliest and most sensitive weeks of development. You can see the full picture of this hormonal pathway in our guide to how GLP-1 medications work.

If you are planning a pregnancy

This is where planning changes everything. If you have it in mind to try for a pregnancy, the most important step is to talk it through with your clinician ahead of time, before stopping anything on your own.

That conversation usually covers three things: when to stop semaglutide to respect the roughly two-month window, how to support weight management during the planning period without the medication, and what to expect in terms of appetite and habits once the effect fades. It is not a decision you make alone or overnight; it is a plan built together and matched to your situation. This is exactly the kind of moment where physician-led care and steady care coaching help most, so the timing fits your life rather than catching you off guard.

Many people also ask about contraception during this stage, and for good reason: the plan to stop the medication and the plan to try for a pregnancy go hand in hand. If it is not the right time yet, keeping a reliable contraceptive method while taking semaglutide is part of the conversation; and when the time does come, stopping is coordinated around the window the label advises. The underlying idea is simple: line up the moment of conception with the moment the medication has already cleared the body, and that comes from planning rather than improvising.

If you are weighing treatment options with your clinician before or after this stage, our guide to semaglutide vs tirzepatide explains how the two molecules differ. The decision about which to use, and when, always belongs to a licensed clinician.

If you find out you are pregnant while taking semaglutide

This is the scenario that causes the most anxiety, so it is worth saying calmly and precisely: do not panic and do not change anything on your own. Contact your clinician right away.

The action the FDA label describes is to discontinue semaglutide when the pregnancy is recognized, and to advise the patient of the risk to the fetus. But the how and the next steps are coordinated by your care team, who knows your full history. An unplanned pregnancy during treatment is not a reason to panic; it is a reason for a quick call to your clinician. Novo Nordisk also maintains a pregnancy exposure registry to follow these cases, something your clinician can walk you through.

If you want to understand what it feels like to come off the medication and which effects are normal, our guide to GLP-1 side effects can help you know what to expect.

What if I took a dose before I knew I was pregnant?

This is one of the most common worries, and it deserves a careful answer. The FDA label is clear on a point that anxiety often drowns out: the available data are insufficient to establish a drug-associated risk of major birth defects or miscarriage. In other words, there is no confirmation that an early exposure causes harm; what exists is not enough information to rule it out, which is why the approach is one of caution.

It also helps to have context on the baseline numbers. The label itself notes that in the U.S. general population, the background risk of major birth defects in recognized pregnancies is about 2 to 4 percent, and the risk of miscarriage is about 15 to 20 percent. Those numbers exist in every pregnancy, with or without medication. Pointing to them is not meant to minimize the situation, but to keep fear from filling the gaps with conclusions the evidence does not support.

The right response, then, is not panic or guilt: it is a call to your clinician to review your case, stop the medication, and follow up with your care team. Having taken one or several doses before you knew is a known and manageable situation, not an emergency to solve alone online.

After pregnancy and breastfeeding

The stage that follows also deserves a clinical conversation, not a rushed decision. On breastfeeding, the FDA label is honest about what is not known: there are no data on whether semaglutide is present in human milk, or on its effects on a breastfed infant or on milk production. In lactating rats the medication was detected in milk, which points toward caution.

For that reason, resuming treatment while breastfeeding is an individual decision made with your clinician, weighing the benefits of breastfeeding against your clinical need for the medication. There is no single right answer for everyone: there is the right answer for your situation, and you decide that with your care team.

The essentials, in short

GLP-1 medications like semaglutide are not recommended during pregnancy. The FDA label advises discontinuing semaglutide at least two months before a planned pregnancy because of its long half-life, and stopping it once a pregnancy is recognized. Human data are limited and animal studies showed potential fetal harm, so caution is the correct approach. And above all: do not stop or change a prescribed medication on your own. Talk to your clinician about the timing and the plan that fit your situation.

GLP-1 medications are FDA-approved for specific indications. Eligibility is determined by a clinician. This is general education and does not replace your clinician’s advice.

Want to plan with real support?

At REMEVi you can talk with a physician-led care team that helps you plan safely, with your history and your timing at the center of the decision, plus transparent pricing and coaching along the way. Real medical care, no rush. Visit remevihealth.com to get started.

Your Health. Your Terms.